This list is an analysis based on recent market events. It's not an investment recommendation.
Operating as a clinical-stage enterprise, Duality Biotherapeutics, Inc. concentrates on pioneering next-generation antibody-drug conjugate (ADC) therapies and proprietary duality immune toxin antibody conjugate (ITAC) solutions. The firm was founded by Zhu Zhong Yuan on July 3, 2019, and its main offices are situated in Shanghai, China.
FAQs
What is Duality Biotherapeutics stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on OTC Link exchange Duality Biotherapeutics stocks are traded under the ticker DYBTY.
When is the next Duality Biotherapeutics earnings date?▼
Duality Biotherapeutics is going to release the next earnings report on March 23, 2027.
What were Duality Biotherapeutics earnings last quarter?▼
DYBTY earnings for the last quarter are -1.5 USD per share, whereas the estimation was N/A USD resulting in a N/A surprise. The estimated earnings for the next quarter are N/A USD per share.
What is Duality Biotherapeutics revenue for the last year?▼
Duality Biotherapeutics revenue for the last year amounts to 260.57M USD.
What is Duality Biotherapeutics net income for the last year?▼
DYBTY net income for the last year is -363.97M USD.
How many employees does Duality Biotherapeutics have?▼
As of November 7, 2026, the company has 231 employees.
In which sector is Duality Biotherapeutics located?▼
Duality Biotherapeutics operates in the Health & Wellness sector.
When did Duality Biotherapeutics complete a stock split?▼
Duality Biotherapeutics has not had any recent stock splits.
Where is Duality Biotherapeutics headquartered?▼
Duality Biotherapeutics is headquartered in Shanghai, China.